State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

Clinically-Relevant Updates in ALL in Adults

Insights from 2023 ASH Annual Meeting

R. Cassaday

Updated Results from the BLAST and TOWER Studies: Safety and Efficac…

Michael Burke

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

How Are Targeted Therapies Redefining the Treatment Paradigm in ALL …

SOHO Brazil 2024

J. Burger

Controversies and Recommendations for the Treatment of ALL and Lymph…

Indy Hematology Review

W. Stock

Overview of Hematopoietic Cell Transplantation

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

R. Salit

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Improving…

Insights from 2023 ASCO® Annual Meeting

L. Shune

State of the Art and Next Questions: ALL

SOHO Highlights: State of the Art and Next Questions

E. Jabbour

Treatment Strategies in MDS and ALL: Removing Bad Humor & Targeting …

Indy Hematology Review

R. Stone

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Chronic GVHD: A Case-Based Discussion

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

L. Perry

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone…

Insights from 2023 ASH Annual Meeting

M. Luskin